Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biostate PK, Efficacy and Safety in Von Willebrand Disease
NCT00941616Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jun 2009
- Primary completion
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label trial of factor viii + von Willebrand factor in von Willebrand disease (VWD) (4 arms), sponsored by CSL Limited. Primary endpoints: Haemostatic efficacy at time of non-surgical bleeding (NSB) event, Haemostatic efficacy overall and 5 more. Started Jun 2009; status: completed.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT00941616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941616.